Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Inovio Pharmaceuticals (NASDAQ:INO) reported positive interim results from its Phase 2 study of INO-5401 for the treatment of newly-diagnosed glioblastoma multiforme (GBM), the most common and aggressive type of brain...

November 5, 2019

Developments

Notch Therapeutics to commercialize industrial-scale T cell therapies

Upstart Notch Therapeutics plans to commercialize industrial-scale allogeneic gene-edited T cell therapies to deliver cost-effective treatments to patients with cancer or immune deficiencies. Incubated at Toronto’s...

November 5, 2019

Markets

HCW starts PDS Biotechnology at buy; PT $7

H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...

November 5, 2019

Markets

WB ups Sientra to OP

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform,” saying the company’s near-to-midterm outlook has stabilized and is improving. The stock closed at $6.77 on Nov. 4. Analyst Margaret Kaczor writes that she...

November 5, 2019

Markets

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

November 5, 2019

Markets

Dawson James starts CollPlant Biotechnologies at buy; PT $9

Dawson James Securities initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and $9 price target. The stock closed at $4.62 on Nov. 1. CollPlant’s technology platform mass produces...

November 4, 2019

Executive Moves

Ventripoint names Justin Leushner as CEO

Ventripoint Diagnostics (TSXV:VPT; OTC:VPTDF) appointed Justin Leushner as CEO, replacing Dr. George Adams, who was elected chairman of the board. Mr. Leushner, who was named president of Ventripoint in September, has a...

November 4, 2019

Developments

Liminal BioSciences to sell bioseparations division to KKR

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) signed a binding share purchase agreement for the proposed saleof its Isle of Man-based bioseparations business operated through subsidiary Prometic Bioseparations (PBL) to...

November 4, 2019

Executive Moves

Orthofix appoints Jon Serbousek as president and CEO

Orthofix Medical (NASDAQ:OFIX) appointed Jon Serbousek as president, CEO and a director of its board, effective immediately. Mr. Serbousek succeeds Brad Mason, who previously announced his retirement. Mr. Mason has...

November 1, 2019

Developments

IntelGenx scaling-up cannabis-infused oral film production

IntelGenx (TSXV:IGX; OTCQX:IGXT) reported on progress in its cannabis-infused VersaFilm product co-development program with partner, Tilray (NASDAQ:TLRY). “We are currently conducting scale-up activities for an...

October 31, 2019

Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Notch Therapeutics to commercialize industrial-scale T cell therapies

HCW starts PDS Biotechnology at buy; PT $7

WB ups Sientra to OP

HCW starts aTyr Pharma at buy; PT $8

Dawson James starts CollPlant Biotechnologies at buy; PT $9

Ventripoint names Justin Leushner as CEO

Liminal BioSciences to sell bioseparations division to KKR

Orthofix appoints Jon Serbousek as president and CEO

IntelGenx scaling-up cannabis-infused oral film production

Follow Us

Subscribe

General

More

Subscribe